Evidence-based decision-making for vaccine introductions: Overview of the ProVac International Working Group's experience

Abstract

Introduction Pan American Health Organization’s (PAHO) ProVac Initiative aims to strengthen countries’ technical capacity to make evidence-based immunization policy. With financial support from the Bill and Melinda Gates Foundation, PAHO established the ProVac International Working Group (IWG), a platform created for two years to transfer the ProVac Initiative’s tools and methods to support decisions in non-PAHO regions. Methods In 2011, WHO Regional Offices and partner agencies established the IWG to transfer the ProVac framework for new vaccine decision support, including tools and trainings to other regions of the world. During the two year period, PAHO served as the coordinating secretariat and partner agencies played implementing or advisory roles. Results Fifty nine national professionals from 17 countries received training on the use of economic evaluations to aid vaccine policy making through regional workshops. The IWG provided direct technical support to nine countries to develop cost-effectiveness analyses to inform decisions. All nine countries introduced the new vaccine evaluated or their NITAGs have made a recommendation to the Ministry of Health to introduce the new vaccine. Discussion Developing countries around the world are increasingly interested in weighing the potential health impact due to new vaccine introduction against the investments required. During the two years, the ProVac approach proved valuable and timely to aid the national decision making processes, even despite the different challenges and idiosyncrasies encountered in each region. The results of this work suggest that: (1) there is great need and demand for technical support and for capacity building around economic evaluations; and (2) the ProVac method of supporting country-owned analyses is as effective in other regions as it has been in the PAHO region. Conclusion Decision support for new vaccine introduction in low- and middle-income countries is critical to guiding the efficient use of resources and prioritizing high impact vaccination programs.

Vaccination access in Primary Care from the user's perspective: senses and feelings about healthcare services

“…It is worth noting that the decision to include or exclude vaccinations offered and the population of choice is supported by technical and scientific bases, such as cost-effectiveness studies, immunobiological safety, production capacity of laboratories and the feasibility of distribution and storage. 18,19 Access to Vaccination in Primary Care Duarte DC, Oliveira VC, Guimarães EAA, Viegas SMF Great dissatisfaction was revealed by the participants of the present study regarding unavailability for the entire population of Influenza vaccine. The Influenza vaccine has been offered since 1999 by the Ministry of Health of Brazil, through annual campaigns to target populations, 4 and since its introduction, there has been a significant reduction in hospitalizations due to Influenza-related causes, especially in the elderly population, 20 directly impacting the reduction of hospitalization costs due to complications of the disease.…”

A systematic review of health economic evaluations of vaccines in Brazil

“…34 The interest in the field led to a recent expansion of the ProVac Initiative to other WHO regions. 35 Recent upward trend in the publication of HEE on vaccines was also noted in systematic reviews of studies published in Spain (from 2005), China (from 2010) and Canada (from 2002). 3,36,37 In Brazil, the MoH request for HEE to incorporate new vaccines into the NIP had a great impact on the field development, encouraging and shaping the scientific production, and promoting human resources training in the area.…”

Vaccines are different: A systematic review of budget impact analyses of vaccines

“…Only three studies took place in middleincome countries (Philippines, Thailand and South Africa). In low-and middle-income countries, where the disease burden is often greater -such as for rotavirus, pneumococcal and cervical cancer -the need of a decision-making process based on evidence for incorporating new vaccines, to contribute to the efficient use of resources and prioritization of high-impact vaccination programs is even more important [33]. Recently, Brazil and Colombia began demanding a BIA study along with a cost-effectiveness evaluation, when incorporating new technologies.…”